Clinical Research

FDA Places Clinical Hold on REGENXBIO's RGX‑121 After Spine MRI Findings

Regulators have ordered additional imaging and longer follow‑up to determine whether the asymptomatic spinal nodules found in trial participants are linked to the AAV gene therapy which has paused near‑term approval plans.